Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10M | 12M | 14M | 20M | 46M |
| Gross Profit | 2M | 3M | 4M | 4M | 9M |
| Operating Income | -2M | -4M | 486K | 2M | 8M |
| EBITDA | 339K | -2M | 2M | 5M | 12M |
| Net Income | -1M | -3M | 112K | 865K | 6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.20
-25.58% today
1Y Change
-100.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
WORK Medical Technology Group Ltd. (WOK) is a Healthcare stock with listed on NASDAQ. The stock last traded around $3.20 and down 100.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -14.4%, EPS growth of -1270.7%, a dividend yield of 0.0%. What stands out right now is revenue -14.4%, EPS -1270.7%, free cash flow +142.8% with operating margin -25.3% and ROIC -9.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WOK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WOK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WOK Max Drawdown
-100.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WOK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$45.9M
+132.7% YoY
FY Net Income
$6.0M
+588.6% YoY
Free Cash Flow
-$7.2M
-69.5% YoY
Revenue Growth
-14.4%
EPS Growth
-1270.7%
Gross Margin
23.8%
Net Margin
-10.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10M | 12M | 14M | 20M | 46M |
| Gross Profit | 2M | 3M | 4M | 4M | 9M |
| Operating Income | -2M | -4M | 486K | 2M | 8M |
| EBITDA | 339K | -2M | 2M | 5M | 12M |
| Net Income | -1M | -3M | 112K | 865K | 6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 7M | 2M | 731K | 509K |
| Total Assets | 33M | 36M | 30M | 26M | 31M |
| Total Liabilities | 12M | 20M | 19M | 14M | 19M |
| Shareholder Equity | 18M | 13M | 10M | 10M | 10M |
| Total Debt | 6M | 13M | 9M | 6M | 7M |
| Net Debt | 2M | 7M | 7M | 6M | 6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-217.8% YoY
Capital Expenditures
60K
+97.0% YoY
Free Cash Flow
7M
-69.5% YoY
Key ratios
Gross Margin
23.8%
Operating Margin
-25.3%
Net Margin
-10.9%
ROE
-6.9%
Debt / Equity
0.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.